Introduction {#S0001}
============

The coming of anti-retroviral therapy (ART) and its widespread availability in many settings has reduced the mortality rate among people living with human immunodeficiency virus (PLHIV).[@CIT0001] As the longevity of PLHIV improves as a result of ART, improvement of health-related quality of life (HRQoL) these patients has become an important issue for clinicians, researchers, and policymakers.[@CIT0002] According to the world health organization (WHO), quality of life is defined as an individuals' perception of their position in life in the context of the culture and value systems in which they live and concerning their goals, expectations, standards, and concerns.[@CIT0003] This definition considers individuals' satisfaction on their physical, psychological, social relationships, environment, and spiritual aspects of their life.[@CIT0003] Though the physical well-being is improved with ART, it does not guarantee mental and social well-being among PLHIV.[@CIT0004]

Routine intake of antiretroviral drugs is mandatory to achieve or to maintain virologic and immunologic outcomes.[@CIT0005] However, these are not the only outcomes that should be taken into consideration. In any chronic disease (both infectious and non-infectious), assessing HRQoL has become an essential outcome of therapy. HRQoL assessments provide valuable feedback about care-related interventions and they are very important in treatment outcomes analyses. HRQoL is vital to clinical practice because it is used to track changes in functional status over time for chronic illness, evaluate and monitor treatment effects, improve patient-provider communication, and adherence to medications.[@CIT0006] HRQoL among human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) can be affected by several factors which may be categorized into individual, service delivery, community, and social-demographic factors. Some of the factors are intertwined, for instance, educational attainment may be linked to self-care. Through education, an individual can be equipped with self-care skills. Marital status is linked to social support because in most cases, married persons have families that can be a source of social support. Service delivery factors, like type and duration of ART regimen and concomitant medications for other illnesses, should be considered.[@CIT0007]

Various HRQoL assessment tools have been used in PLHIV, most commonly as part of research trials. These tools can be classified as either generic or disease-specific, with the former designed to be used in a variety of populations to provide a general overview of HRQoL and the latter designed to measure health status in specific groups (diseases). A long ago, many HRQoL measures used in HIV research were developed before the HAART era, including the Medical Outcomes Survey HIV Health Survey (MOS-HIV), Functional Assessment of HIV Infection (FAHI), HIV Overview of Problems-Evaluation System (HOPES), HIV/AIDS Targeted QOL (HAT-QOL), AIDS Health Assessment Questionnaire (AIDS-HAQ), Multidimensional QOL Questionnaire for HIV/AIDS (MQoL-HIV). However, these measures may not fully address the impact of contemporary treatments and not sensitive& specific to detect HRQoL changes. Unfortunately, much as a measurement of HRQoL data is important, patients perceive the effects of ART on their quality of life as a trade-off between poorer quality of life and being alive.[@CIT0008]

Therefore, currently, to measure the impact of contemporary treatments, sensitive measure for HRQoL was developed& used in some of the pieces of literature and called as patient-reported outcomes quality of life HIV instrument (PROQOL-HIV). We used this HRQoL measuring scale for our current study to assess the association of contemporary HAART regimens with health-related quality of life. HRQoL information from this study will inform healthcare practitioners not only about the physical but also the mental wellbeing of their patients and overall functionality. This will increase their suspicion index of detecting illness, thus enhancing the quality of service provided to their patients. By and large, our study aimed to assess health-related quality of life and factors associated with HRQoL among HAART initiated HIV infected patients on follow up at Jimma University Medical Center, Ethiopia.

Methods {#S0002}
=======

Study Design and Settings {#S0002-S2001}
-------------------------

This is a cross-sectional study done among HIV infected patients who initiated on HAART at the ART clinic of Jimma University Medical Center (JUMC) from April to August 2016. Patients were eligible for the present study if they were on HAART at least for 6 months, aged 18 years, and if they gave their informed consent to participate in the study. Currently, a total of 7288 HIV--infected individuals were registered and attending JUMC comprehensive chronic care and training center. Out of these, 4,277 (58.6%) were on HAART, and the remaining 3011 (41.4%) were HAART naive. The center works 7 days a week in an outpatient setting and provides holistic HIV care by employing clinicians, counselors and social workers.

Sample Size and Sampling Techniques {#S0002-S2002}
-----------------------------------

A total of 160 adult patients who fulfill the inclusion criteria and accepted to participate were included in the study. The sampling of the study population was done based on a systematic random sampling technique. There was no difference between those participating and those who did not. But we included only adult patients who initiated on HAART, as the PROQOL-HIV scale included the impact of the treatment.

Data Collection Tools and Outcome Measure {#S0002-S2003}
-----------------------------------------

In this study, the principal investigators and research assistants used English versions validated PROQOL-HIV tool.[@CIT0009] The tool was also translated to other two local languages (i.e. Afaan Oromoo and Amharic), which was also back-translated to English for consistency by health care professionals native to the languages. The version of the tool was determined by the language for which the participant felt comfortable to be interviewed. This tool was administered via face to face interview. The dimensions were measured on a Likert scale and mainly quantitative data was collected. Other information such as socio-demographic, behavioral& clinical data was included in the questionnaire to meet the objectives of the study other than the HRQoL items. The PROQOL-HIV scale is used to summarize a patient's HRQoL as eight-scale scores within the past two weeks. PROQOL-HIV questionnaire administration and scoring are fast, which comprises 38 items, 1 reverse-scored item, and 4 summated subscales.

These eight sub-scales (factors) is categorized into the following domains: physical health and symptoms (PHSs, 9 items), treatment impact (TI, 10 items), emotional distress (ED, 4 items), health concerns (HCs, 4 items), body change (BC, 4 items), intimate relationships (IR, 3 items), social relationships (SR, 2 items), and stigma (ST, 2 items). However, a single item assessing general health during the past 2 weeks and four further items dealing with religious beliefs, finance, parenthood, and satisfaction with care are used to gather additional information related to patient's HRQoL and are not part of the scoring scheme in this study.

The sub-scales were derived from summed Likert item values (range 0--4 points) expressed as a final score on a 0--100 scale with higher values indicating better HRQoL. The mean±SD scores for each of the domains were calculated for each domain.

Participants rated the extent to which they had experienced each of the 38 items over the past 2 weeks on a 5-point scale ranging from 1=never to 5=always. One item was an exception, where response categories ranged from 1= very good to 5=very poor. The scoring was done based on the number of items included in each domain (see the formula below). The main properties, including the validity and reliability of the questionnaire and comparisons with other commonly used HRQoL instruments, have previously been described elsewhere.[@CIT0009]
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IR: has three questions (items) to be asked & the maximum score is 3x4=12

Cronbach's alpha was calculated to determine the internal consistency of the PROQOL-HIV tool. All domains of the PROQOL-HIV had a high value of Cronbach's alpha (α \> 0.7). The Cronbach's alpha coefficient of physical health and symptoms (0.74), emotional distress (0.72), health concerns (0.70), body change (0.72), social relationships (0.79), intimate relationships (0.71), stigma (0.81), and treatment impact (0.78) were adequate, indicating acceptable reliability of the questionnaire.

Data Collection Procedure {#S0002-S2004}
-------------------------

Two trained data collectors (nurses) interviewed the study participants and reviewed patient charts and medical records for the respective information after all data collection tools were pre-tested. Data about HRQoL were interviewed by using a standard questionnaire mentioned above (PROQOL-HIV). Patient self-reports and using medication (s) as a proxy indicator for chronic non --communicable disease diagnosis was used to identify the presence of non-communicable diseases (NCDs). Since the study was conducted in a clinic setting and individual factors like CD4+ cell counts, co-morbidities, self-reported symptoms, and immunological state were considered.

Data Processing & Analysis {#S0002-S2005}
--------------------------

We calculated descriptive statistics for patient characteristics. Demographic data were reported as frequencies and percentage or mean (SD) values. Only patients with complete data on all explanatory variables were considered in the final model and included in the analyses. Participant characteristics and HRQoL outcomes were tabulated and stratified. Proportions were compared for categorical variables. Continuous variables were presented as medians and inter-quartile ranges unless otherwise stated. The main study outcome was HRQoL as measured by PROQOL-HIV, which were also reported as mean (SD) values. Linear regression was used to identify the associations between PROQOL-HIV scale domains and demographic, behavioral, clinical and immunological characteristics of the patients. Results were presented as B-coefficient, standard error, and p-value. Statistical analysis was performed using IBM SPSS software, version 20.0 (IBM Corp., Armonk, NY). Statistical significance was set at p \< 0.05.

Ethical Considerations {#S0002-S2006}
----------------------

Ethical clearance & approval was obtained from the institutional review board (IRB) of Jimma University. The data that were collected from the JUMC ART clinic was preceded by a formal request letter from Jimma University. Written informed consent was taken from each study participant after a clear orientation of the study objective. The raw data were not made available to anyone and not used as the determinant of the participant. All steps in data collection and compilation were conducted and supervised by the principal investigators. Strict confidentiality was assured through anonymous recording and coding of questionnaires and placed in a safe place. The patient got full right not to participate and as well as leave the study at any time during the study time.

Results {#S0003}
=======

Characteristics of the Study Participants {#S0003-S2001}
-----------------------------------------

In this study, all the variables were assessed cross-sectionally during the patient's interview. Out of a total of 160 participants, 63.13% were females. The mean ($\documentclass[12pt]{minimal}
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\end{document}$9.45 years. About half of them were in the age range of 35--50 years. About 55% of study participants were married and about 76.25% were living with immediate family. Most of them attended formal education and only 11.25% could not read and write. Behavioral measurements of study participants showed that about 52.5%, 18.13%, and 16.25% were alcohol consumers, chat chewer and smoker respectively ([Table 1](#T0001){ref-type="table"}).Table 1Socio-Demographic and Behavioral Characteristics of Study ParticipantsVariablesNumber (%)SexMale59(36.87)Female101(63.13)Age (years)Mean±SD41.47±9.4518--3556(35)35--5079(49.4)≥ 5025 (15.6)BMI (kg/m^2^)\<1822 (13.75)18 −24.9115 (71.88)≥2523(14.37)Marital statusSingle16 (10)Married88 (55)Divorced34 (21.25)Widowed22 (13.75)Educational statusCould not read and write18 (11.25)Primary92(57.50)Secondary31(19.38)College and above19(11.87)ResidenceRural31 (19.38)Urban129(80.62)Monthly income (USD)No regular income78 (48.75)\<4017 (10.62)40--8031 (19.38)80--12016 (10)≥12018 (11.25)Living StatusLiving with immediate family122 (76.25)Living with extended family28 (17.50)Living alone10 (6.25)Job/OccupationGov't employee38(23.75)Non-gov't employee14 (8.75)Self-employed51 (31.88)Unemployed57(34.37)Behavioral MeasuresCurrent smoker26 (16.25)Current alcohol user \*\*84(52.50)Chat chewer29 (18.13)Herbal/traditional medicine use ^¥^40 (25)[^1]

Concerning clinical and immunological characteristics of study participants, approximately two-thirds and 35.62% of patients were on cotrimoxazole (CTX) and Isoniazid (INH) preventive therapy, respectively. About two-thirds of patients had tuberculosis (TB) treatment history. The most common type of TB was pulmonary TB (45.37%). The median baseline CD~4~+ cell count was 182.00 cells/µL) \[Interquartile range (IQR): 104.53--262.4 cells/µL\]. At enrollment, more than half of patients had advanced diseases (WHO stage III--IV and CD~4~+ cell count less than 200 cells/µL). The median follows up duration was 74.75 months \[IQR: 57.23--104.63 months\] ([Table 2](#T0002){ref-type="table"}).Table 2Clinical and Immunological Characteristics of Study ParticipantsVariablesNumber (%)CTX prophylaxisYes105 (65.63)No55 (34.37)INH prophylaxisYes57 (35.62)No103(64.38)TB treatment historyYes108(67.50)No52(32.50)Type of TBPulmonary49 (45.37)Disseminated29 (26.85)Unknown30 (27.78)Clinical stage (WHO)Stage I13(8.12)Stage II45 (28.13)Stage III72 (45)Stage IV30 (18.75)Eligibility reason to HAARTCD~4~+ count55 (34.40)Clinical19 (11.90)CD~4~+ count & clinical86 (53.70)Mean time on HAART (in months)49.13±17.09Median duration with HIV (in months)74.75 (IQR: 57.23--104.63)Base line CD4+ count (cells/µL)Median (IQR)182.00 (104.53--262.4)\<20097 (60.63)200 −34949 (30.62)350 -- 49910 (6.25)≥5004 (2.5)Time elapsed from diagnosis to HAART initiation (in months)Within the same month62 (38.75)1--2464 (40)≥2444 (21.25)Functional StatusWorking143(89.37)Ambulatory17 (10.63)HAART RegimenNevirapine based59 (36.88)Efavirenz based89 (56.25)Second line11 (6.87)Prior regimen changeYes100(62.5)No60(37.5)NCD comorbidityHypertension22 (13.75%)Diabetes19 (11.88)Cardiac (Heart failure)7 (4.37)Asthma/COPD^\#^6 (3.75)Mental Illness3 (1.88)Epilepsy3 (1.88)Multimorbidity\*\*20 (12.50)[^2]

Health-Related Quality of Life (HRQoL) {#S0003-S2002}
--------------------------------------

Concerning HRQoL, the overall mean$\documentclass[12pt]{minimal}
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\end{document}$ SD score of PROQOL-HIV domains is 77.58 ±15.11, 58.32 ±7.79, 61.75± 17.95, 85.07 ±15.67, 76.92 ± 20.52, 80.00 ±16.83, 74.37 ± 1.47, 81.45 ± 8.17 for \[physical health and symptoms (PHS), emotional distress (ED), health concerns (HC), body change (BC), intimate relationships (IR), social relationships (SR), stigma (ST) and treatment impact (TI)\] domains, respectively ([Figure 1](#F0001){ref-type="fig"}).Figure 1Mean (±SD) Scores of 8 domains PROQOL-HIV of study participants \[Error bars with standard errors\].**Abbreviations:** PHS, Physical health and symptoms; ED, emotional distress; HC, health concerns; BC, body change; IR, intimate relationships; SR, social relationships; ST, stigma; TI, treatment impact.

Assessment of patient-reported outcome quality of life with demographic and behavioral data showed that there was no statistically significant difference in mean score among male and female participants. Younger patients had a relatively lower mean score in all domains of the PROQOL-HIV scale. All patients have a lower mean score on the emotional distress domain as compared to other domains. Patients with irregular income and positive for behavioral measures had a lower mean score of patient-reported outcome quality of life measures ([Table 3](#T0003){ref-type="table"}).Table 3Mean (±SD) Scores of 8 Domains PROQOL-HIV on Demographic and Behavior Data of Study ParticipantsVariablesPROQOL-HIV Domains \[Mean (SD)\]PHSEDHCBCIRSRSTTISexMale78.48(13.69)59.64 (6.49)62.50 (18.53)85.59(16.70)77.82 (18.35)79.45 (17.02)75.42 (1.62)81.65(8.47)Female77.06(15.93)57.5 (8.40)61.32(17.69)84.78(15.11)76.40 (21.76)80.32 (16.80)73.76 (1.38)81.34(8.03)P value0.6520.0910.1620.2450.6740.2810.0730.647Age18 -- 3575.89(17.33)61.13(17.27)69.48(19.83)82.25(16.84)78.12 (22.56)85.22(18.69)70.08(1.52)78.25 (10.81)35--5071.21(14.30)59.57(7.47)63.21(17.27)85.28(15.63)76.16(18.72)82.75(15.92)67.05(1.39)83.03 (5.86)≥ 5066.22 (11.92)59.25(5.44)62.25(15.67)80.75(11.42)76.66 (21.92)82.00 (13.05)65.50(1.46)83.60 (5.05)P value0.1920.2630.0850.4320.5320.4620.0960.145BMI (kg/m^2^)\<1876.45 (13.75)56.79 (8.40)55.97(19.26)84.78(14.57)79.34 (19.60)82.60 (16.31)72.28 (1.59)80.97(9.49)18 −24.977.19 (15.72)58.05(7.83)61.12 (17.96)84.26 (16.23)76.38 (20.50)79.38 (17.44)73.35 (1.43)80.83 (8.21)≥2580.67 (13.41)61.14 (6.51)70.65(13.51)89.40 (13.64)77.17(22.22)80.43 (14.51)81.52 (1.40)85.00 (5.48)P value0.2320.1530.1850. 3420. 3120. 6420.1910.151Marital statusSingle77.08 (17.37)54.29 (8.13)55.85 (16.21)83.20 (16.25)88.54 (15.17)73.43 (16.37)63.28 (1.32)73.12 (11.74)Married78.15 (14.97)59.58 (7.92)63.70 (18.02)84.87 (16.24)74.81 (20.60)80.39 (16.82)75.85 (1.45)82.50 (7.65)Divorced78.51 (14.12)57.72 (7.22)62.68 (17.09)85.47 (15.13)73.03 (21.12)78.67 (17.27)73.16 (1.51)81.47 (6.74)Widowed74.24 (15.94)57.10 (7.03)56.81 (19.47)86.64 (14.60)82.95 (19.49)85.23 (15.73)78.40 (1.28)83.29 (5.63)P value0.5510.1350. 1170. 2020. 1260. 1420.2010.127Educational statusCannot read & write76.85 (16.74)57.64 (8.72)56.59 (16.25)81.63 (16.26)70.55 (18.52)76.25 (17.28)73.61 (1.41)81.25 (9.36)Primary77.98 (14.23)58.63 (7.46)62.16 (16.08)85.86 (14.99)77.08 (20.43)80.84 (15.66)76.08 (1.29)82.74 (6.55)Secondary76.61 (13.50)57.45 (7.64)60.68 (19.51)85.08 (15.20)73.65 (20.64)77.02 (18.84)69.75 (1.82)79.35 (9.63)College and above77.92 (20.52)58.88 (9.15)66.44 (24.58)83.55 (19.67)78.07 (23.27)79.60 (19.20)74.34 (1.69)78.81 (10.55)P value0.0580. 0670. 1710. 1420. 2260. 1440.1110.131ResidenceRural80.28 (15.57)58.67 (7.16)63.30 (16.51)76.69 (16.27)60.64 (19.29)71.85 (18.21)65.80 (1.36)72.09 (7.16)Urban86.93 (14.99)58.23 (7.96)71.38 (18.32)84.68 (15.56)71.03 (20.78)79.55 (16.53)74.03 (1.50)81.29 (8.41)P value0.0980. 0780. 2170. 1320. 2570. 0630.1330.354Monthly income (USD)No regular income67.92 (14.60)57.53 (7.76)56.85 (16.16)75.33 (14.86)69.48 (20.39)70.28 (17.04)64.35 (1.42)81.66 (8.25)\<4075.81 (16.13)58.45 (7.63)60.66 (20.82)83.82 (15.15)77.94 (23.37)83.82 (13.81)72.05 (1.36)81.32 (6.73)40- 8078.13 (13.08)60.48 (7.96)65.72 (19.62)83.67 (16.90)72.31 (18.92)79.83 (18.72)77.02 (1.61)82.90 (5.98)80--12076.21 (20.21)56.64 (8.37)60.93 (19.96)89.45 (16.57)75.00 (23.17)76.56 (15.72)70.31 (1.63)78.59 (11.29)≥12078.08 (16.02)59.37 (7.19)64.93 (18.33)83.68 (17.56)74.53 (18.84)78.47 (17.04)75.69 (1.45)80.69 (9.23)P value0.1570. 0870. 2610. 1240. 5620. 4140.5210.061Living StatusLiving with immediate family76.86 (15.33)58.29 (8.09)61.98 (18.73)84.27 (16.09)75.34 (20.42)79.09 (17.19)74.28 (1.48)81.04 (8.71)Living with extended family79.86 (14.19)58.25 (6.81)60.04 (15.71)87.72 (14.17)81.54 (21.31)83.48 (15.97)74.55 (1.57)82.41 (6.50)Living alone78.08 (15.11)58.33 (7.65)62.50 (15.30)86.11 (14.91)82.40 (18.83)81.94 (15.45)75.00 (1.25)83.61 (4.69)P value0.3580. 2370. 9010. 5210. 7210.5150.4310.292Job/OccupationGov't employee78.36 (14.79)58.88 (7.49)64.14 (17.59)84.70 (15.62)76.53 (18.36)76.97 (17.56)73.68 (1.47)81.31 (7.55)Non-gov't employee69.44 (20.26)56.69 (9.64)54.01 (21.03)83.03 (17.91)70.23 (24.83)75.00 (13.86)68.75 (1.68)78.03 (11.85)Self-employed80.01 (14.01)60.17 (6.72)64.46 (17.02)86.02 (16.18)75.00 (20.13)84.31 (16.17)77.20 (1.40)83.23 (6.10)Unemployed77.14 (14.88)56.95 (7.91)59.43 (16.83)84.90 (15.08)79.55 (21.21)80.18 (16.52)74.29 (1.43)81.65 (8.02)P value0.0830. 0680. 0870. 4110. 4370.3520.1310.212Behavioral MeasuresSmokerYes75.21 (15.39)58.17 (7.45)62.25 (19.48)84.13 (16.88)75.32 (20.06)75.48 (18.19)75.48 (1.74)81.05 (9.54)No78.04 (15.07)58.34 (7.88)61.66 (17.72)85.26 (15.48)77.23 (20.67)80.87 (16.48)74.16 (1.42)81.52 (7.91)P value0.2530. 1580. 0690. 1210. 0770.1520.2330.444Alcohol useYes76.71 (14.45)58.25 (7.46)61.90 (17.80)85.04 (16.00)76.68 (20.11)79.46 (16.53)74.55 (1.48)81.22 (8.98)No78.54 (15.85)58.38 (8.20)61.59 (18.24)85.11 (15.40)77.19 (21.09)80.59 (17.24)74.17 (1.47)81.71 (7.21)P value0.4710. 2170. 1310. 2570. 0980.4760.3810.267Chat ChewerYes79.69 (14.79)58.62 (6.11)65.73 (15.72)86.00 (16.33)73.27 (21.75)79.74 (17.49)77.15 (1.33)83.27 (5.30)No77.12 (15.20)58.25 (8.14)60.87 (18.35)84.87 (15.58)77.73 (20.24)80.05 (16.75)73.75 (1.50)81.04 (8.64)P value0.7220.3860.1900.3230.3580.1230.0960.345Herbal/traditional medicine useYes73.61 (16.36)55.00 (10.12)58.75 (19.36)85.00 (15.64)69.16 (25.77)78.75 (16.71)72.50 (1.64)82.25 (5.19)No77.85 (15.05)58.54 (7.60)61.95 (17.91)85.08 (15.72)77.44 (20.12)80.08 (16.89)74.50 (1.46)81.40 (8.34)P-value0.0710. 3170. 0540. 5270. 0880. 6610.3210.143[^3]

The impact of clinical and immunological factors on patient-reported outcome quality of life revealed that those patients on preventive therapy (both Isoniazid and Cotrimoxazole) had a higher mean score on all domains of PROQOL-HIV scale, with the significant association on PHS, ED, HC domains (p≤0.05). Previous TB infection resulted in a lower mean score on the health concern (p=0.036) domain. Those patients who have advanced diseases (WHO clinical stage III & IV) had a very low mean score on PHS (p=0.006), ED (p=0.009) and HC (p=0.018) domains. Non-communicable disease comorbidity resulted in a significantly lower mean score in all domains of patient-reported outcome quality of life ([Table 4](#T0004){ref-type="table"}).Table 4Mean (±SD) Scores of 8 Domains PROQOL-HIV on Clinical & Immunologic Factors of Study ParticipantsVariablesPROQOL-HIV Domains \[Mean (SD)\]PHSEDHCBCIRSRSTTICTX prophylaxisYes78.57 (15.28)65.09 (7.84)70.89 (18.40)86.00 (16.00)78.09 (20.42)80.59 (17.59)74.52 (1.52)81.47 (8.17)No71.70 (14.74)58.75 (7.75)63.40 (17.11)85.22 (15.18)74.69 (20.72)78.86 (15.37)74.09 (1.39)75.40 (8.24)P value0.0160.0500.0260.1450.2730.1810.0730.047INH prophylaxisYes78.99 (13.76)58.44 (8.05)62.28 (16.06)85.63 (14.89)78.94 (21.31)80.70 (16.88)74.34 (1.46)82.50 (7.41)No76.80 (15.82)58.25 (7.69)61.46 (18.99)84.76 (16.15)75.80 (20.09)79.61 (16.87)74.39 (1.48)80.87 (8.54)P value0.0270.1400.1410.1240.1370.0450.1190.062TB treatment historyYes71.62 (14.96)58.39 (7.65)61.45 (17.29)83.30 (14.80)75.46 (20.02)78.09 (16.74)74.76 (1.40)81.57 (7.43)No77.51 (15.58)58.17 (8.16)72.37 (19.43)84.61 (17.47)79.96 (21.40)79.80 (17.17)73.53 (1.61)81.20 (9.59)P value0.0520.5310.0360.4200.1210.2450.1120.181Type of TBPulmonary78.57 (14.56)60.20 (7.06)63.01 (15.30)86.73 (13.71)74.14 (19.85)82.14 (16.13)75.25 (1.33)83.06(5.77)Disseminated73.46 (14.01)56.89 (8.24)56.89(18.92)86.20 (13.71)77.01 (19.24)77.58 (16.15)75.00 (1.49)81.12 (9.05)P value0.0150.0670.0470. 2340.0920.0860.2370.081Clinical stage (WHO)Stage I78.63 (12.56)59.13 (8.31)64.90 (15.54)85.57 (19.32)82.05 (19.79)90.38 (15.43)76.92 (1.33)81.56 (14.43)Stage II67.45 (10.56)57.24 (8.20)59.65(12.32)84.37 (16.42)77.27 (20.04)75.00 (16.61)73.57 (1.50)77.32 (13.57)Stage III56.56 (17.71)59.11(7.09)60.41 (7.84)84.46 (15.90)77.50(21.79)79.51 (18.32)74.30 (1.48)76.32 (15.89)Stage IV40.45 (12.37)56.25 (5.63)43.75 (8.19)80.53(12.45)50.00 (9.45)75.54 (14.43)72.90 (1.54)75.00 (13.68)P value0.0060.0090.0180. 0940.0780.1210.2310.118Eligibility reasonCD~4~+ count77.77 (16.80)57.50 (8.19)60.90 (17.84)84.20 (17.08)78.78 (19.89)78.40 (17.75)74.54 (1.48)80.27(10.22)Clinical81.57 (14.32)57.89 (6.53)60.19 (15.47)91.11 (10.88)73.24 (20.33)84.21 (14.93)73.68 (1.49)81.57 (6.07)CD~4~+ count & clinical76.58 (14.14)58.93 (7.82)62.64 (18.66)84.30 (15.48)76.55 (21.06)80.08 (16.64)74.41 (1.48)82.18 (7.01)P value0.5310.6720.0770. 4410.8820.3330.3140.566Base line CD4+ count (cells/µL)\<20058.76 (17.81)63.22(7.29)60.73(9.84)78.46 (11.90)77.89(17.29)79.49 (16.32)76.30 (11.48)77.32 (13.89)≥20079.00 (14.56)61.23(11.41)64.92 (13.45)82.57 (15.23)80.05 (17.19)8200 (15.43)74.82 (11.13)80.56 (14.13)P value0.0150.1130.1510. 4410.5010.1830.1290.163Time elapsed till HAART initiation (in months)Within the same month82.25(16.84)78.12(22.56)78.51 (14.12)57.72 (7.22)62.68 (17.09)76.68 (20.11)79.46 (16.53)74.55 (1.48)1--2476.03 (20.78)78.08(15.11)58.33 (7.65)62.50 (15.30)78.43 16.7883.48 (15.97)74.55 (1.57)82.41 (6.50)≥2457.43 (8.88)80.67(13.41)61.14 (6.51)70.65(13.51)78.04 (15.07)58.34 (7.88)61.66 (17.72)85.26 (15.48)P value0.0670.5310.0610. 1410.5640.0710.0920.059Functional StatusWorking75.22(18.49)70.08(1.32)78.25 (10.83)75.80 (1.36)82.09 (7.16)85.08 (15.20)73.65 (20.64)77.02 (18.84)Ambulatory51.88 (13.58)62.25(16.84)59.12 (22.56)65.22(18.69)64.27 (16.09)68.34 (20.42)69.09 (17.19)71.28 (1.48)P value0.0080.0140.0270. 0540.0750.0650.1110.221Regimen ChangeYes77.41 (15.21)58.37 (7.85)62.06 (18.42)85.12 (15.91)76.83 (19.44)79.75 (16.26)75.37 (1.41)81.30 (8.52)No77.87 (15.06)68.22 (7.76)61.25 (17.29)85.00 (15.40)77.08 (22.37)80.41 (17.88)72.70 (1.56)81.70 (7.61)P value0.5210.0630.0580. 2540.1120.3450.2130.876NCD comorbidityYes67.10 (14.67)57.34 (8.06)59.45 (17.87)73.75 (14.80)74.16 (20.60)77.65 (16.48)72.81 (1.57)77.37 (8.31)No80.06 (15.23)59.29(7.44)64.06 (17.85)86.40 (16.48)79.68 (20.18)82.34 (16.95)75.93 (1.36)81.53 (8.07)P value0.0010.0630.0180. 0540.0040.0210.5110.312[^4]

Univariate regression analysis of potential factors associations with the 8 domains PROQOL-HIV scores were presented in [Table 5](#T0005){ref-type="table"}, with co-variates grouped according to an indication of socio-demographic, behavioral, clinical & immunological factors. Concerning factors associated with HRQoL, co-morbidity with NCD(s), duration with HIV and HAART, advanced disease, TB infection and being on the second line HAART regimen from clinical factors and smoking and alcohol use history from behavioral measures were negatively associated with HRQoL across all domains of PROQOL-HIV. Chronic NCD(s) were significantly associated with physical health and symptoms domain (β=−14.340; p\<0.001), health concern (β=−4.014; (p\<0.05), social (β=−4.213; p\<0.05) and intimate relationships (β=−5.006; p\<0.05)) domains and also being in WHO clinical stage III and IV at baseline were negatively related across all domains; significantly physical health of the patient (β=−2.709; p\<0.05).Table 5Linear Regression Estimates of Univariate Factors of the Mean (SE) Increase/Reduction (+/−) in PROQOL-HIV Domains According to the Indication of Socio-Demographic, Behavioral, Clinical and Immunologic FactorsVariablesPROQOL-HIV Domains \[Mean (SE)\]PHSEDHCBCIRSRSTTRTSocio demographic factorsMale sex−0.673 (2.875)−1.454 (2.071)+0.423 (1.786)+0.035 (1.394)+0.416 (1.131)+0.383(1.612)+0.334 (1.554)+0.316 (1.343)Female Sex−2.937 (1. 587)−1.454 (1.071)−0.13 2 (1.346)−0.136(2.332)−0.416 (1.101)+0.038(1.012)+0.444 (1.405)+0.636 (2.303)Age+0.030 (0.144)+0.211(0.102)+0.324 (1.574)+0.126 (0.117)+0.631(0.112)+0.475(0. 717)+0.064 (0. 077)+0.231(0.064)Getting married−0.172 (2.798)+1.947(2.006)+0.164 (0. 089)+0.233 (1.007)+1.215 (1.501)+0.223 (1.241)+0.225 (1.507)+2.326 (1.290Baseline weight−0.069 (0.145)+0.201(0.103)−1.235 (1.567)−2.115 (2.517)−0.105 (1.981)−0.622 (1.231)+0.056 (0.078)+0.117(0.067)Body mass index (kg/m^2^)−1.254 (0.385)+0.602(0.273)−1.066 (1.178)−1.655 (1.597)−0.233 (1.227)−0.019 (1.731)+0.166 (0.207)+0.202(0.179)Having formal education−0.280 (4.405)+3.521(3.155)+0.166 (0.207)+0.115 (2.517)+1.225 (1.007)−0.005 (0.507)−1.093 (2.372)+0.229 (2.051)Unemployment−2.671 (2.950)−2.234 (2.119)−1.273 (2.332)+0.621 (1.112)−2.315 (1.500)−1.225 (1.507)−1.730 (1.587)−0.296 (1.377)Lack of regular income−1.335 (1.772)−1.980 (1.996)−2.330 (2.587)+0.217 (1.561)−2.701(2.203)−1.221 (1.592)−1.854 (1.493)+0.417 (1.296)Urban residence+6.773 (3.480)+1.167(2.531)+1.854 (1.493)+1.624 (1.089)+1.223 (1.234)+1.453 (1.077)+2.599 (1.886)+0.798 (1.639)Living with family−5.796 (5.731)−2.222(4.131)−2.569 (1.866)+1.330 (1.387)−1.183 (1.732)−1.173 (1.352)−2.646 (3.091)−2.450 (2.670)Behavioral measuresSmoking history−1.829 (3.770)−0.287 (2.713)−1.664 (2.431)−1.772 (1.556)−2.324 (2.221)−1.422 (1.236)−0.994 (2.031)−0.472 (1.756)Alcohol use history−3.862 (2.770)−0.209 (2.004)−1.984 (2.231)−0.678 (1.731)−1.472 (1.756)−0.694 (1.033)−0.712 (1.501)−0.490 (1.297)Chat chewing+5.549 (3.586)+2.369(2.592)−0.712 (1.501)−0.832 (1.443)−0.622 (1.500)+1.212 (1.301)−0.153 (1.947)+2.226 (1.673)Clinical and immunological factorsCPT use+8.381 (2.854)^‡^+0.616 (2.104)+1.660 (1.231)+1.304 (1.502)+1.070 (1.102)+1.050 (1.005)+1.870 (1.572)+0.067 (1.365)TB history−0.224 (2.972)+0.297 (2.137)−1.870 (1.662)−1.142 (1.232)−1.570 (1.608)−1660 (1.442)−0.755 (1.600)+0.372 (1.383)IPT use+1.008 (2.906)+1.079 (2.088)−0.755 (1.230)+1.008 (2.103)+1.132 (2.108)+1.208 (2.126)+0.400 (1.566)+1.626 (1.347)Duration on HAART−1.075 (0.041)−1.041 (0.030)−1.400 (1.536)−0.025 (0.022)−1.033 (0.028)−0.014 (0.027)+0.004 (0.034)+0.033 (0.019)NVP based regimen+0.293 (3.163)+4.372 (2.248)+1.204 (0.122)+0.144 (1.113)+0.711 (1.432)+0.630 (1.903)+0.744 (1.703)+2.227(1.462)EFV based regimen+1.041 (2.800)−1.319 (2.012)+0.744 (1.703)+0.132(1.137)+0.961(1.109)+0.617(1.267)+0.432(1.509)+0.080 (1.304)2^nd^ line HAART regimen−2.734 (5.280)−6.194 (3.768)−2.432(1.609)−1.335(2.264)−1.114 (1.848)−1.002(1.010)−2.517 (2.840)−6.301 (2.409)^‡^Baseline CD4+ count−0.001(0.011)+0.007 (0.008)−1.147 (1.840)+0.113 (0.120)+0.173(0.461)+0.014 (0.126)+0.013 (0.006)^‡^+0.004 (0.005)Time elapsed till HAART+0.096 (0.070)−0.043 (0.051)+0.213 (1.126)−1.096 (1.170)−1.143 (1.005)−0.196 (0.270)+0.006 (0.038)−0.023 (0.033)Duration with HIV−0.047(0.041)−0.019 (0.029)−1.216 (1.037)−1.216(1.217)−1.311 (1.007)−1.421(1.010)−0.004 (0.022)+0.015 (0.019)Stage III & IV (WHO)−2.709 (2.912)^‡^−1.388 (2.097)−0.234 (1.122)−1.833 (1.197)−1.650 (2.007)−1.400(2.127)−0.356 (1.573)+0.596 (1.354)NCD comorbidity−14.340(2.539)^†^−2.969 (1.988)−4.014 (1.483)^‡^−3.523 (1.137)−5.006 (1.803) ^‡^−4.213(1.601) ^‡^−3.099 (1.480)−0.156 (1.296)[^5]

Cotrimoxazole and isoniazid preventive therapy had a positive relationship with patient-reported outcome quality of life across the domains. Several socio-demographic factors and behavioral measures were more strongly associated with the physical health and symptoms domain than with the rest of the domains ([Table 5](#T0005){ref-type="table"}).

Discussion {#S0004}
==========

To our knowledge, in Ethiopia, a few facility-based studies have been conducted to assess the HRQoL among PLHIV and the impact of ART on them.[@CIT0010],[@CIT0011] Given the longevity achievable with current prophylactic and therapeutic strategies for persons with HIV infection, quality of life has emerged as a significant medical outcome measure and its enhancement as an important goal.[@CIT0011] Consequently, the impact of HIV infection on the dimensions of quality of life, including physical health and symptoms, treatment impact, emotional distress, health concerns, body change, intimate relationships, social relationships, and stigma, has emerged as a key issue for persons infected with HIV. Our current study, using the PROQOL-HIV instrument, assessed the HRQoL among PLHIV in JUMC and attempted to clarify the associated factors.

We assessed mean (±SD) of HRQoL scores of our participants and performed a quantitative analysis concerning demographic, behavioral, clinical and immunological information. Accordingly, we found that there was no significant difference in the quality of life among male and female. However, there was a slight difference in the stigma domain (p=0.073) and emotional distress (p=0.091) component. Despite the lack of general agreement about gender differences in HRQoL, our current finding partially supported by other studies, on which women mostly reported lower HRQoL than men.[@CIT0012]--[@CIT0014] This could be explained by the prevalence of mood disorders, anxiety disorders and psychosomatic disorders in females, which are suspected to affect this quality of life domains.[@CIT0015],[@CIT0016]

Our study revealed that though statistically not significant, patients with older age scored lower mean score, all PROQOL-HIV scale domains, which is similar to other studies.[@CIT0017]--[@CIT0021] This could be related to physical senescence among the elderly[@CIT0013]--[@CIT0022] and also a positive relationship between younger age and better mental health.[@CIT0022] Similar to our study, different reports from different settings showed, even as if the diagnosis of HIV infection, in and of itself, can have deleterious ramifications, including the discontinuation of work, limitations in social activity, and dependence on others. Limited social support and poor coping skills also can negatively affect HRQoL.[@CIT0023],[@CIT0024] Socio-demographic factors, such as older age, female gender, unemployment, and low income, have been associated with poor HRQoL.[@CIT0024]--[@CIT0027]

Unemployment negatively influenced all HRQoL domains; largely physical, emotional and social health status. Different studies showed as if employment had a positive indicator for good physical health.[@CIT0025],[@CIT0028]--[@CIT0030] Since getting a job constitutes a big part of the daily life of people; it can provide structure, a social support network, role identity and meaning.[@CIT0031] As well our analysis showed that patients with education reported better quality of life, possibly due to better knowledge about their treatment and disease. This result is similar to another study among HIV/AIDS patients.[@CIT0018]

Different cross-sectional studies[@CIT0011],[@CIT0020] and a longitudinal study[@CIT0022] showed a negative association of comorbidity burden on HRQoL, especially on physical health. Likewise, our current findings showed similar results. On the univariate analysis of linear regression, co-existence of NCDs showed negative association across all domains of quality of life measures, especially on physical health symptoms and concerns, social health and intimate relationships, there was a statistically significant association. So, concluding that physical functioning was most affected by the addition of other chronic health problems. Social functioning, mental health functioning, social relationships were also strongly associated with chronic disease burden, which is consistent with other studies.[@CIT0011],[@CIT0032],[@CIT0033] Besides this, NCD increased emotional distress, including worrying worseness of HIV infection in the near future as well as had a negative impact on HAART medication experience. These effects may be attributed to the non-communicable disease itself and/or its medications.

All patients had a relatively better mean score (quality of life) on treatment-related impact (TRT) domain as compared to other domains. Despite their statistical insignificance, some of the patient's baseline information showed a positive association with treatment-related issues. This could be due to the continuous improvements in ART leading to fewer side-effects and possibilities of combination preparations.[@CIT0034],[@CIT0035] Some of the variables like living with family (immediate or extended), being on second-line HAART medications (p\<0.05) and non-adherence (p\<0.05) showed a significant negative influence on TRT. On PROQOL-HIV instrument, questions were dealing with the size of pills, the number of pills, and frequency of administration as well as taking ARTs in presence of family/friends, which could negatively influence health-related quality of life.

Besides this, patients who were initiated on second-line HAART may feel like changing his/her HIV medicine near future, which will have a negative impact on the quality of life.

This study also showed prophylactic medications use (i.e. CPT and IPT) had a positive association on the HRQoL of life in all domains, suggesting the importance of these interventions on the improvement of the quality of life. Especially, CPT use had a significant positive association on the physical health and symptoms, which may be related to its effect in the prevention of disabling opportunistic infection(s). Concerning behavioral measures, there was a negative relationship between alcohol intake and smoking and health-related quality of life, which is also reported by recent studies.[@CIT0036],[@CIT0037] This may be explained by accelerating in physical function declining, and increased levels of clinical illness and physical and cognitive impairment as well as sleep disturbances.

Limitations of the Study {#S0005}
========================

This study has limitations. The study sample size was relatively small, and participants were recruited from one tertiary care hospital. Therefore, the generalization of the findings should be cautious and as well as further study is needed to generalize the result and factors affecting the quality of life domains. And, the PROQOL-HIV quality of life scale is not validated for Ethiopia. The strength of this study is, it uses a more contemporaneous scale to measure HRQoL, which has been validated and presents moderate to high correlation to other common scales used in the field.

Conclusions {#S0006}
===========

In conclusion, our study revealed that HRQoL among PLHIV were negatively influenced by several socio-economic, behavioral, clinical and immunological factors. Unemployment/lack of regular income, smoking and alcohol intake, tuberculosis infection, second-line HAART medication, non-adherence, and non-communicable disease comorbidity had a negative influence on health-related quality of life.

The burden of chronic NCDs among PLHIV on HRQoL showed a statistically significant negative influence on all dimensions of quality of life measures. Therefore, with HRQoL emerging as a key issue for HIV--infected patients, its routine assessment at each clinic visit would be very crucial. Further research is needed to examine the HRQoL of HIV--infected people, by using this current PROQOL-HIV scale, as ours is the first report used this quality of life measuring scale in Ethiopia.

This research study is dedicated to our citizens lost their lives on Irreechaa festival, the Oromo's thanksgiving holiday, on Sunday, 02-October-2016 G.C., at Hora Arsadi, Bishoftu, Oromia, Ethiopia. We would like to acknowledge study participants for their time and dedication to this study and the staff working at TB-HIV follow-up clinic in Jimma University medical center, Ethiopia, for their support during the study. Our deepest heartfelt gratitude also goes to Jimma University for providing grant funds for this research. We have also special thanks to Dr. Martin Duracinsky, for his collaboration in getting the health-related quality of life measuring scale questionnaire.
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[^1]: **Notes:** ^¥^Those who use holy water as complementary medicine were included; 1USD=25 Ethiopian Birr. \*\*Locally prepared alcohol such as "Tella" was included.

    **Abbreviations:** SD, Standard Deviation, BMI, Body Mass Index; USD, United States Dollar.

[^2]: **Notes:** ^\#^Only one COPD patient included; \*\*co-occurrence 2 or more disease together.

    **Abbreviations**: CTX, Cotrimoxazole; INH, Isoniazid; TB, Tuberculosis; WHO, World Health Organization; CDC, Centers for Disease Control and Prevention; SD, Standard Deviation; ~CD4~+, Cluster Differentiation, HAART, Highly Active Antiretroviral Therapy; COPD, chronic obstructive pulmonary disease; NCD, Non-communicable disease.

[^3]: **Abbreviations:** BMI, Body mass index; USD, United States Dollar; Gov't, Government.

[^4]: **Abbreviations:** NCD, Non-communicable disease; TB, Tuberculosis; CTX, Cotrimoxazole; INH, Isoniazid; WHO, World Health Organization; HAART, Highly active antiretroviral therapy.

[^5]: **Notes:** ^‡^P\<0.05; ^†^P\<0.001.

    **Abbreviations:** EFV, Efavirenz; NVP, Nevirapine; NCD, non- communicable disease; IPT, Isoniazid preventive therapy; CPT, Cotrimoxazole preventive therapy; PHS, Physical health and symptoms, TRT, treatment related impact, ED, emotional distress, HCs, health concerns, BC, body change, IR, intimate relationships, SR, social relationships, ST, stigma.
